• Natalie Rodríguez Z, Juan Tordecilla C, Myriam Campbell B, Pilar Joannon S, Carlos Rizzardini L, Verónica Soto A, and Patricia Verdugo L.
• Unidad de Hemato-Oncología, Hospital de Niños Roberto del Río, Santiago, Chile. rodriguez@med.uchile.cl
• Rev Chilena Infectol. 2005 Sep 1;22(3):223-7.

AbstractChemotherapy associated febrile neutropenia is an important cause of morbidity and mortality in pediatric patients with cancer. The use of granulocyte-colony stimulating factor (G-CSF) post chemotherapy decreases the risk of infectious complications but its efficacy during the febrile neutropenic episode remains controversial. Thirty five episodes of high-risk febrile neutropenia were randomized into two treatment arms, 18 received antibiotics and G-CSF (group A) and 17 received antibiotics only upon admission (group B). Both groups were comparable in terms of demographic and clinical characteristics. No significant differences between groups were found in duration of hospitalization (mean group A 7 vs group B 8 days), antibiotic treatment (mean 7 vs 8 days), fever (3 vs 2 days), nor of neutropenia (4 vs 3 days). One patient in group A died after RSV infection. Considering these results and a literature review, we propose that G-CSF should not be recommended in children during the course of their febrile neutropenic episode.

25 keywords...

hide…